Coya Therapeutics, Inc. (COYA) Dividend History

Coya Therapeutics, Inc. (COYA) is a biopharmaceutical company focused on developing therapies for neurodegenerative and neuroinflammatory diseases. The company leverages cell-based and immunomodulatory approaches to address conditions such as amyotrophic lateral sclerosis (ALS) and other neurological disorders. Coya aims to advance innovative treatments that can modify disease progression and improve patient outcomes.

12645 Memorial Dr., Suite F1 #305, Houston, TX, 77024
Phone: 650.739.3939
Website:

Dividend History

Coya Therapeutics, Inc. currently does not pay dividends

Company News

  • Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS

    Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.

    Zacks Investment Research
    Featured Companies: AGEN PBYI
  • Rare Stock Picks In August 2023 - From 34 Discerning Analysts

    We've compiled a list of August investment picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. See their Buy recommendations here.

    Seeking Alpha
    Featured Companies: ARLO ATUS AZO BDTX CFG CHWY CRM DCTH EXPI FOUR FSI GSM HOOD HSY LEVI LOW MP MSGS NDLS NVDA PH PYPL SMIN TACT TDOC TPYP VTR VTS X
  • Analyst Expectations for Coya Therapeutics's Future

    Within the last quarter, Coya Therapeutics (NASDAQ:COYA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 4 0 0 0 0 According to 8 analyst offering 12-month price targets in the last 3 months, Coya Therapeutics has an average price target of $19.75 with a high of $28.00 and a low of $9.00. Below is a summary of how these ...Full story available on Benzinga.com

    Benzinga
  • The Latest Analyst Ratings for Coya Therapeutics

    Coya Therapeutics (NASDAQ:COYA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 5 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 These 9 analysts have an average price target of $18.33 versus the current price of Coya Therapeutics at $4.715, implying upside. Below is a summary of how these 9 analysts rated Coya Therapeutics over ...Full story available on Benzinga.com

    Benzinga
  • Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday

    Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close at $36.39 on Tuesday. Telsey Advisory Group lowered the price target for Oxford Industries, Inc. (NYSE: OXM) from $125 to $115. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Oxford Industries shares fell 5.8% to $101.00 in pre-market trading. Morgan Stanley cut the price target for Carrier Global Corporation (NYSE: CARR) from $49 to $47. Morgan Stanley analyst Betsy Graseck downgraded the stock from Overweight to Equal-Weight. Carrier Global shares fell 3.3% to $44.11 in pre-market trading. Jefferies slashed Wynn Resorts, Limited (NASDAQ: WYNN) price target from $135 ...

    Benzinga
    Featured Companies: CARR CURV EAT EPAM FICO MMC OLLI OXM WYNN
Dividend data last updated 06/08/2025 00:03:14 UTC